Keyphrases
Systemic Sclerosis
100%
Scleroderma
74%
Interstitial Lung Disease
25%
Randomized Placebo-controlled Trial
21%
Pulmonary Hypertension
21%
Calcinosis
20%
Placebo
17%
Clinical Trials
14%
Digital Ulcers
14%
Cyclophosphamide
14%
Lung
13%
Diffuse Cutaneous Systemic Sclerosis
13%
Systemic Sclerosis-associated Interstitial Lung Disease
12%
Oral Cyclophosphamide
10%
Forced Vital Capacity
9%
Pulmonary Arterial Hypertension
8%
Classification Criteria
7%
EUSTAR
7%
Modified Rodnan Skin Score (mRSS)
7%
Risk Factors
7%
Raynaud's Phenomenon
7%
Abatacept
7%
Hypertension Diagnosis
7%
African American
7%
Scleroderma Lung Disease
7%
Autoantibodies
6%
European League against Rheumatism (EULAR)
6%
Mycophenolate Mofetil
6%
American College of Rheumatology
6%
Right Heart Catheterization
5%
Tolerability
5%
Odds Ratio
5%
Adverse Events
5%
Scleroderma Renal Crisis
5%
Pharmacology, Toxicology and Pharmaceutical Science
Systemic Sclerosis
76%
Scleroderma
43%
Placebo
35%
Pulmonary Hypertension
17%
Interstitial Lung Disease
17%
Cyclophosphamide
14%
Finger Ulcer
11%
Adverse Event
11%
Lung Disease
8%
Abatacept
7%
Clinical Trial
6%
Raynaud Phenomenon
6%
Mycophenolate Mofetil
5%
Tolerability
5%
Fibrosis
5%
Medicine and Dentistry
Systemic Scleroderma
57%
Scleroderma
40%
Calciphylaxis
20%
Interstitial Lung Disease
14%
Pulmonary Hypertension
12%
Placebo
10%
Cyclophosphamide
7%
Clinical Trial
7%
Finger Ulcer
7%
Lung
5%
Silo-Filler's Disease
5%